Abstract #0142

Cardiac 31P MRS in breast cancer patients undergoing chemotherapy

Gillian Macnaught^1,2, Christopher Rodgers³, Martin Denvir⁴, Olga Oikonomidou^5,6, Annette Cooper¹, William Clarke³, Heather McVicars⁶, Larry Hayward⁶, Saeed Mirsadraee¹, and Scott Semple^1,4

¹Clinical Research Imaging Centre, University of Edinburgh, Edinburgh, United Kingdom, ²the MRC Centre for inflammation Research, University of Edinburgh, Edinburgh, United Kingdom, ³RDM Cardiovascular Medicine, University of Oxford, Oxford, United Kingdom, ⁴BHF Centre for Cardiovascular Science, University of Edinburgh, Edinburgh, United Kingdom, ⁵Edinburgh Cancer Research Centre, University of Edinburgh, Edinburgh, United Kingdom, ⁶Edinburgh Cancer Centre, NHS Lothian, Edinburgh, United Kingdom

Anthracyclines are chemotherapy agents widely used to treat cancer but that can also induce cardiotoxicity. Techniques are required to provide an earlier warning of cardiotoxicity before irreversible myocardial damage. 9 subjects were recruited to this on-going 31P MRS study to detect changes in cardiac energetics of breast cancer patients undergoing chemotherapy. Between pre- and mid-chemotherapy four subjects experienced a greater than 20% decrease in their cardiac PCr/ATP ratio, 1 subject experienced a 13.8% decrease in left ventricular ejection fraction (LVEF) and all had increased troponin levels. Ultimately this study aims to determine whether changes in PCr/ATP precede changes in LVEF.

This abstract and the presentation materials are available to members only; a login is required.

Join Here